These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15855726)

  • 1. Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases.
    Yamanaka H; Nakajima M; Hara Y; Katoh M; Tachibana O; Yamashita J; Yokoi T
    Drug Metab Pharmacokinet; 2005 Apr; 20(2):135-43. PubMed ID: 15855726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes.
    Nakajima M; Sakata N; Ohashi N; Kume T; Yokoi T
    Drug Metab Dispos; 2002 Nov; 30(11):1250-6. PubMed ID: 12386132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions.
    Nakajima M; Yamanaka H; Fujiwara R; Katoh M; Yokoi T
    Drug Metab Dispos; 2007 Sep; 35(9):1679-86. PubMed ID: 17576806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin.
    Kim PM; Winn LM; Parman T; Wells PG
    J Pharmacol Exp Ther; 1997 Jan; 280(1):200-9. PubMed ID: 8996197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
    Allabi AC; Gala JL; Horsmans Y
    Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients.
    Argikar UA; Cloyd JC; Birnbaum AK; Leppik IE; Conway J; Kshirsagar S; Oetting WS; Klein EC; Remmel RP
    Epilepsy Res; 2006 Sep; 71(1):54-63. PubMed ID: 16815679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo.
    Caraco Y; Muszkat M; Wood AJ
    Pharmacogenetics; 2001 Oct; 11(7):587-96. PubMed ID: 11668218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of 5-(p-hydroxyphenyl)-5-phenylhydantoin and studies relating to the disposition of phenytoin in man.
    Witkin KM; Bius DL; Teague BL; Wiese LS; Boyles LW; Dudley KH
    Ther Drug Monit; 1979; 1(1):11-34. PubMed ID: 553326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.
    Fritz S; Lindner W; Roots I; Frey BM; Küpfer A
    J Pharmacol Exp Ther; 1987 May; 241(2):615-22. PubMed ID: 3572817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy.
    Aliwarga T; Cloyd JC; Goel V; Brundage RC; Marino SE; Leppik IE; Remmel RP
    Ther Drug Monit; 2011 Feb; 33(1):56-63. PubMed ID: 21233690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
    Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH
    Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.
    Erickson-Ridout KK; Sun D; Lazarus P
    Pharmacogenet Genomics; 2012 Aug; 22(8):561-76. PubMed ID: 22565219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
    Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
    Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms.
    Fujiwara R; Nakajima M; Yamanaka H; Nakamura A; Katoh M; Ikushiro S; Sakaki T; Yokoi T
    Drug Metab Dispos; 2007 May; 35(5):747-57. PubMed ID: 17293379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the effects of common UDP glucuronosyltransferase (UGT) 1A6 and UGT1A1 polymorphisms on cis- and trans-resveratrol glucuronidation.
    Iwuchukwu OF; Ajetunmobi J; Ung D; Nagar S
    Drug Metab Dispos; 2009 Aug; 37(8):1726-32. PubMed ID: 19406951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro characterization of the glucuronidation pathways of licochalcone A mediated by human UDP-glucuronosyltransferases.
    Xia YL; Dou TY; Lv X; Ge GB
    Xenobiotica; 2019 Jun; 49(6):671-677. PubMed ID: 30044687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of 5-(3,4-Dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin (Dihydrodiol) and quantitative studies of phenytoin metabolism in man.
    Maguire JH; Kraus BL; Butler TC; Dudley KH
    Ther Drug Monit; 1979; 1(3):359-70. PubMed ID: 555579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphenol-A glucuronidation in human liver and breast: identification of UDP-glucuronosyltransferases (UGTs) and influence of genetic polymorphisms.
    Street CM; Zhu Z; Finel M; Court MH
    Xenobiotica; 2017 Jan; 47(1):1-10. PubMed ID: 26999266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
    Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
    Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.